Company Interview / Cancer free: Imugene's exciting trial progress

Leslie Chong of Imugene (ASX:IMU) shares exciting progress in cancer trials, revealing a major milestone as a bile tract cancer patient remains in full remission for two years. Leslie highlights the diseases targeted, including colon cancer, and expresses delight for the patient's renewed lease on life and time with loved ones.

The company sees hope as the FDA grants fast track and orphan designation, working collaboratively to market the drug swiftly. Patents extend to 2040, allowing for significant timelines. Despite this, Leslie underlines the importance of patient enrolment and trial data to expedite the transition to phase two and beyond.

Leslie confirms financial preparedness, noting the R&D tax rebate and lean approach to clinical trials, with 75% dedicated to development. Despite fluctuations in share prices, Leslie emphasises the strength of Imugene's infrastructure, focusing on patient outcomes to positively influence shareholder value.